R Costa1, A Morrison, J Wang, C Manithody, J Li, A R Rezaie. 1. Department of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, University at Buffalo-SUNY, Buffalo, NY, USA.
Abstract
BACKGROUND: Modulation of energy substrate metabolism may constitute a novel therapeutic intervention against ischemia/reperfusion (I/R) injury. AMP-activated protein kinase (AMPK) has emerged as a key regulator of favorable metabolic signaling pathways in response to myocardial ischemia. Recently, we demonstrated that activated protein C (APC) is cardioprotective against ischemia/reperfusion (I/R) injury by augmenting AMPK signaling. OBJECTIVES: The objective of this study was to determine whether the APC modulation of substrate metabolism contributes to its cardioprotective effect against I/R injury. METHODS: An ex vivo working mouse heart perfusion system was used to characterize the effect of wild-type APC and its signaling-proficient mutant, APC-2Cys (which has dramatically reduced anticoagulant activity), on glucose transport in the ischemic heart. RESULTS: Both APC and APC-2Cys (0.2 μg g(-1)) augment the ischemic stress-induced translocation of the glucose transporter (GLUT4) to the myocardial cell membrane, leading to increased glucose uptake and glucose oxidation in the ischemic heart (P < 0.05 vs. vehicle). Both APC derivatives increased the autophagic flux in the heart following I/R. The activity of APC-2Cys in modulating these metabolic pathways was significantly higher than APC during I/R (P < 0.05). Intriguingly, APC-2Cys, but not wild-type APC, attenuated the I/R-initiated fatty acid oxidation by 80% (P < 0.01 vs. vehicle). CONCLUSIONS: APC exerts a cardioprotective effect against I/R injury by preferentially enhancing the oxidation of glucose over fatty acids as energy substrates in the ischemic heart. Given its significantly higher beneficial metabolic modulatory effect, APC-2Cys may be developed as a potential therapeutic drug for treating ischemic heart disease without risk of bleeding.
BACKGROUND: Modulation of energy substrate metabolism may constitute a novel therapeutic intervention against ischemia/reperfusion (I/R) injury. AMP-activated protein kinase (AMPK) has emerged as a key regulator of favorable metabolic signaling pathways in response to myocardial ischemia. Recently, we demonstrated that activated protein C (APC) is cardioprotective against ischemia/reperfusion (I/R) injury by augmenting AMPK signaling. OBJECTIVES: The objective of this study was to determine whether the APC modulation of substrate metabolism contributes to its cardioprotective effect against I/R injury. METHODS: An ex vivo working mouse heart perfusion system was used to characterize the effect of wild-type APC and its signaling-proficient mutant, APC-2Cys (which has dramatically reduced anticoagulant activity), on glucose transport in the ischemic heart. RESULTS: Both APC and APC-2Cys (0.2 μg g(-1)) augment the ischemic stress-induced translocation of the glucose transporter (GLUT4) to the myocardial cell membrane, leading to increased glucose uptake and glucose oxidation in the ischemic heart (P < 0.05 vs. vehicle). Both APC derivatives increased the autophagic flux in the heart following I/R. The activity of APC-2Cys in modulating these metabolic pathways was significantly higher than APC during I/R (P < 0.05). Intriguingly, APC-2Cys, but not wild-type APC, attenuated the I/R-initiated fatty acid oxidation by 80% (P < 0.01 vs. vehicle). CONCLUSIONS:APC exerts a cardioprotective effect against I/R injury by preferentially enhancing the oxidation of glucose over fatty acids as energy substrates in the ischemic heart. Given its significantly higher beneficial metabolic modulatory effect, APC-2Cys may be developed as a potential therapeutic drug for treating ischemic heart disease without risk of bleeding.
Authors: Annie M Behrend; Cary O Harding; James D Shoemaker; Dietrich Matern; David J Sahn; Diane L Elliot; Melanie B Gillingham Journal: Mol Genet Metab Date: 2011-10-01 Impact factor: 4.797
Authors: Thati Madhusudhan; Hongjie Wang; Beate K Straub; Elisabeth Gröne; Qianxing Zhou; Khurrum Shahzad; Sandra Müller-Krebs; Vedat Schwenger; Bruce Gerlitz; Brian W Grinnell; John H Griffin; Jochen Reiser; Hermann-Josef Gröne; Charles T Esmon; Peter P Nawroth; Berend Isermann Journal: Blood Date: 2011-11-23 Impact factor: 22.113
Authors: Sripal Bangalore; David J Cohen; Neal S Kleiman; Tal Regev-Beinart; Sunil V Rao; Michael J Pencina; Laura Mauri Journal: Circ Cardiovasc Interv Date: 2011-10-04 Impact factor: 6.546
Authors: Congcong He; Michael C Bassik; Viviana Moresi; Kai Sun; Yongjie Wei; Zhongju Zou; Zhenyi An; Joy Loh; Jill Fisher; Qihua Sun; Stanley Korsmeyer; Milton Packer; Herman I May; Joseph A Hill; Herbert W Virgin; Christopher Gilpin; Guanghua Xiao; Rhonda Bassel-Duby; Philipp E Scherer; Beth Levine Journal: Nature Date: 2012-01-18 Impact factor: 49.962
Authors: Lin Wang; Nanhu Quan; Wanqing Sun; Xu Chen; Courtney Cates; Thomas Rousselle; Xinchun Zhou; Xuezhong Zhao; Ji Li Journal: Cardiovasc Res Date: 2018-05-01 Impact factor: 10.787
Authors: Si Chen; Zhenhua Wang; Bo Xu; Xiangquan Mi; Wanqing Sun; Nanhu Quan; Lin Wang; Xingchi Chen; Quan Liu; Yang Zheng; Jiyan Leng; Ji Li Journal: Toxicol Sci Date: 2015-09-04 Impact factor: 4.849